Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06797518 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
A Phase 2 study of Immunoglobulin A Nephropathy and Glomerulonephritis, IGA, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 14
- Study locations
NCT06797518 is a Phase 2 study of Immunoglobulin A Nephropathy and Glomerulonephritis, IGA that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 20 participants, below the 303-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (93% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT06797518, a Phase 2 study of Immunoglobulin A Nephropathy and Glomerulonephritis, IGA, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 14
- Study locations
Study Summary
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quantifying the change in mesangial C3c containing fragments deposition, as an indicator of complement activation, and evaluating a variety of biomarkers related to kidney function, damage, and disease progression, including but not limited to Oxford MEST-C score.
Conditions Studied
Interventions
- DRUG Iptacopan
Study Locations (14)
Other
- Novartis Investigative Site - Ashdod
- Novartis Investigative Site - Hadera
- Novartis Investigative Site - Haifa
- Novartis Investigative Site - Nahariya
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- OSU Wexner Medical Center - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
California
- UCLA Medical Center - Los Angeles
Georgia
- Nephronet Clinical - Buford
Idaho
- CaRe Research - Chubbuck
Nevada
- DaVita Clinical Research - Las Vegas
Texas
- Prolato Clinical Research Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2027-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06797518
The ClinicalTrials.gov registry entry for NCT06797518 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 303-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (93% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Iptacopan is the first listed.
NCT06797518 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Other, Ohio, Alabama.
Frequently Asked Questions
What is clinical trial NCT06797518 about?
NCT06797518 is a clinical study titled "Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN". A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quant...
What is the current status of trial NCT06797518?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-02-21. Estimated completion is 2027-11-27.
What conditions does trial NCT06797518 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy, Glomerulonephritis, IGA.
What interventions are being tested in trial NCT06797518?
The interventions under investigation include: Iptacopan (DRUG).
Who is sponsoring clinical trial NCT06797518?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06797518 being conducted?
This trial has 14 study locations across Alabama, California, Georgia, Idaho, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
COMPLETED · Phase 2
-
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
RECRUITING
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.